US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

Electra Therapeutics / Equity Capital Markets

<ul>
<li>Electra priced an upsized 23.33 million shares at $15.00, but opened flat and closed at $13.25, down 11.7% on persistent selling pressure.</li>
<li>The more-than-four-times oversubscribed book failed to translate into aftermarket support, highlighting a disconnect between headline demand and committed demand.</li>
<li>Electra’s earlier-stage development profile and distant clinical milestones may have contributed to limited investor patience despite a constructive recent biotech IPO backdrop.</li>
</ul>


Electra priced an upsized 23.33 million shares at $15.00, but opened flat and closed at $13.25, down 11.7% on persistent selling pressure.
The more-than-four-times oversubscribed book failed to translate into aftermarket support, highlighting a disconnect between headline demand and committed demand.
Electra’s earlier-stage development profile and distant clinical milestones may have contributed to limited investor patience despite a constructive recent biotech IPO backdrop.


Electra Therapeutics (ETRA): Biotech IPO Finds Little Aftermarket Support Despite Upsize

<ul>
<li>Electra is developing precision immunotherapies designed to selectively eliminate disease-driving immune cells while preserving normal immune function.</li>
<li>Ipsoprubart has generated encouraging early data in malignancy-associated HLH, including 100% overall survival and overall response in 12 frontline patients.</li>
<li>Sector momentum and current demand are constructive, with all four August biotech IPOs trading above issue prices and Electra’s book reportedly oversubscribed.</li>
</ul>


Electra is developing precision immunotherapies designed to selectively eliminate disease-driving immune cells while preserving normal immune function.
Ipsoprubart has generated encouraging early data in malignancy-associated HLH, including 100% overall survival and overall response in 12 frontline patients.
Sector momentum and current demand are constructive, with all four August biotech IPOs trading above issue prices and Electra’s book reportedly oversubscribed.


Electra Therapeutics (ETRA): Electra Looks to Keep Biotech IPO Momentum Charged

Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

<ul><li>✓ IPO Prophet Rating: 7.68/10 🏦 Deal Quality &amp; Underwriters: 8.25/10 Electra Therapeutics is a late clinical-stage biotechnology company developing precision medicines that selectively deplete disease-driving immune cells through the signal regulatory protein family.</li><li>Its lead candidate, ipsoprubart, is a first-in-class pan-SIRP antibody designed to target pathological myeloid and T cells while preserving unaffected immune populations.</li><li>Ipsoprubart is being evaluated as a frontline treatment for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition with high mortality and limited treatment options.</li></ul>

✓ IPO Prophet Rating: 7.68/10 🏦 Deal Quality &amp; Underwriters: 8.25/10 Electra Therapeutics is a late clinical-stage biotechnology company developing precision medicines that selectively deplete disease-driving immune cells through the signal regulatory protein family.Its lead candidate, ipsoprubart, is a first-in-class pan-SIRP antibody designed to target pathological myeloid and T cells while preserving unaffected immune populations.Ipsoprubart is being evaluated as a frontline treatment for secondary hemophagocytic lymphohistiocytosis, a severe hyperinflammatory condition with high mortality and limited treatment options.

<ul><li>Electra Therapeutics, Inc. (ETRA) is preparing to sell approximately 21.67 million shares of common stock on the Nasdaq Global Select Market at an expected price of $14.00 to $16.00 per share.</li><li>At the $15.00 midpoint, the offering would raise approximately $325.0 million and value the clinical-stage biotechnology company at roughly $916.5 million.</li><li>Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers. The shares are expected to begin trading on Friday, September 18, 2026.</li></ul>

Electra Therapeutics, Inc. (ETRA) is preparing to sell approximately 21.67 million shares of common stock on the Nasdaq Global Select Market at an expected price of $14.00 to $16.00 per share.At the $15.00 midpoint, the offering would raise approximately $325.0 million and value the clinical-stage biotechnology company at roughly $916.5 million.Jefferies, TD Cowen, Evercore ISI and Cantor are serving as joint book-running managers. The shares are expected to begin trading on Friday, September 18, 2026.

Electra Therapeutics (ETRA) Targets $325 Million IPO to Advance Precision Immunology Pipeline

<ul>
<li>Electra Therapeutics is targeting a $303 million IPO to advance ipsoprubart through Phase 2/3 development in sHLH and expand its precision immune-cell depletion platform.</li>
<li>Ipsoprubart has shown compelling early efficacy, including 100% eight-week survival and response rates in 12 frontline malignancy-associated HLH patients.</li>
<li>A constructive biotech IPO backdrop and strong underwriting syndicate provide a favorable setup, with Electra offering an attractive risk-reward profile ahead of Friday’s debut.</li>
</ul>


Electra Therapeutics is targeting a $303 million IPO to advance ipsoprubart through Phase 2/3 development in sHLH and expand its precision immune-cell depletion platform.
Ipsoprubart has shown compelling early efficacy, including 100% eight-week survival and response rates in 12 frontline malignancy-associated HLH patients.
A constructive biotech IPO backdrop and strong underwriting syndicate provide a favorable setup, with Electra offering an attractive risk-reward profile ahead of Friday’s debut.


Electra Therapeutics (ETRA): Precision Immune-Cell Depletion Biotech Sets Terms for Same-Week Debut

United States

Electra Therapeutics, Inc. is a biopharmaceutical company. The Company develops precision medicines for the treatment of immune-mediated diseases and cancer. Electra Therapeutics operates in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Electra Therapeutics (ETRA US)

Electra Therapeutics (ETRA): Biotech IPO Finds Little Aftermarket Support Despite Upsize

Electra priced an upsized 23.33 million shares at $15.00, but opened flat and closed at $13.25, down 11.7% on persistent selling pressure.

IPO Boutique

Electra Therapeutics (ETRA): Electra Looks to Keep Biotech IPO Momentum Charged

Electra Therapeutics looks to be the latest biotech IPO to come to market successfully. The company brings a differentiated precision-immunology...

IPO Boutique

IPO Rating: Electra Therapeutics Inc.

✓ IPO Prophet Rating: 7.68/10 🏦 Deal Quality & Underwriters: 8.25/10 Electra Therapeutics is a late clinical-stage biotechnology company...

IPO Prophet

Electra Therapeutics (ETRA) Targets $325 Million IPO to Advance Precision Immunology Pipeline

Electra Therapeutics, Inc. (ETRA) is preparing to sell approximately 21.67 million shares of common stock on the Nasdaq Global Select Market at an...

IPO Prophet

Electra Therapeutics (ETRA): Precision Immune-Cell Depletion Biotech Sets Terms for Same-Week Debut

Electra Therapeutics Looks to Ride Biotech IPO Momentum With $300M Offering. Jefferies, TD Cowen, Evercore ISI, Cantor are among the underwriters...

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)